This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock FSDC vs. APLS, LYEL, XENE, AMRX, ARWR, MIRM, KNSA, NAMS, BLTE, and HRMYShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Apellis Pharmaceuticals (APLS), Lyell Immunopharma (LYEL), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Arrowhead Pharmaceuticals (ARWR), Mirum Pharmaceuticals (MIRM), Kiniksa Pharmaceuticals (KNSA), NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), and Harmony Biosciences (HRMY). These companies are all part of the "medical" sector. FS Development vs. Its Competitors Apellis Pharmaceuticals Lyell Immunopharma Xenon Pharmaceuticals Amneal Pharmaceuticals Arrowhead Pharmaceuticals Mirum Pharmaceuticals Kiniksa Pharmaceuticals NewAmsterdam Pharma Belite Bio Harmony Biosciences Apellis Pharmaceuticals (NASDAQ:APLS) and FS Development (NASDAQ:FSDC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Do institutionals and insiders hold more shares of APLS or FSDC? 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 89.8% of FS Development shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend APLS or FSDC? Apellis Pharmaceuticals currently has a consensus target price of $40.05, indicating a potential upside of 120.05%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Apellis Pharmaceuticals is more favorable than FS Development.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.62FS Development 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is APLS or FSDC more profitable? FS Development has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -34.97%. FS Development's return on equity of 0.00% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Apellis Pharmaceuticals-34.97% -103.11% -28.96% FS Development N/A N/A N/A Does the media refer more to APLS or FSDC? In the previous week, Apellis Pharmaceuticals had 4 more articles in the media than FS Development. MarketBeat recorded 9 mentions for Apellis Pharmaceuticals and 5 mentions for FS Development. Apellis Pharmaceuticals' average media sentiment score of 1.34 beat FS Development's score of 0.00 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apellis Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FS Development 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, APLS or FSDC? FS Development has lower revenue, but higher earnings than Apellis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApellis Pharmaceuticals$775.84M2.95-$528.63M-$1.79-10.17FS DevelopmentN/AN/AN/AN/AN/A Does the MarketBeat Community believe in APLS or FSDC? Apellis Pharmaceuticals received 352 more outperform votes than FS Development when rated by MarketBeat users. CompanyUnderperformOutperformApellis PharmaceuticalsOutperform Votes35266.29% Underperform Votes17933.71% FS DevelopmentN/AN/A SummaryApellis Pharmaceuticals beats FS Development on 10 of the 13 factors compared between the two stocks. Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FSDC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$672.23M$6.81B$5.54B$8.63BDividend YieldN/A2.48%5.27%4.17%P/E RatioN/A8.4226.7319.83Price / SalesN/A264.94404.46150.91Price / CashN/A65.8538.2534.64Price / BookN/A6.547.104.67Net IncomeN/A$143.26M$3.22B$248.14M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$53.71+1.9%N/A+16.1%$672.23MN/A0.00N/AHigh Trading VolumeAPLSApellis Pharmaceuticals4.7125 of 5 stars$18.82-1.7%$40.05+112.8%-55.2%$2.37B$775.84M-9.27770Gap UpLYELLyell Immunopharma3.1432 of 5 stars$7.99-2.8%$20.00+150.3%-79.4%$2.36B$65K-10.11270High Trading VolumeXENEXenon Pharmaceuticals3.6694 of 5 stars$30.72+2.2%$54.82+78.4%-12.1%$2.36B$7.50M-10.89210AMRXAmneal Pharmaceuticals3.4337 of 5 stars$7.45+0.4%$11.50+54.4%+12.5%$2.33B$2.83B-10.967,600ARWRArrowhead Pharmaceuticals3.6198 of 5 stars$16.61+1.3%$42.13+153.6%-39.1%$2.29B$545.21M-3.21400Analyst UpgradeMIRMMirum Pharmaceuticals3.2106 of 5 stars$45.29-1.5%$60.73+34.1%+91.5%$2.24B$379.25M-22.42140KNSAKiniksa Pharmaceuticals3.2424 of 5 stars$29.11+4.3%$38.80+33.3%+50.8%$2.12B$481.17M-207.91220Analyst UpgradeHigh Trading VolumeNAMSNewAmsterdam Pharma2.9677 of 5 stars$18.69-1.3%$43.00+130.1%+5.3%$2.10B$47.14M-9.944BLTEBelite Bio2.6357 of 5 stars$64.82-0.3%$96.67+49.1%+19.2%$2.06BN/A-58.4010Short Interest ↑HRMYHarmony Biosciences4.77 of 5 stars$35.31-0.7%$53.00+50.1%+13.5%$2.03B$744.85M16.73200Positive NewsShort Interest ↑ Related Companies and Tools Related Companies Apellis Pharmaceuticals Competitors Lyell Immunopharma Competitors Xenon Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Kiniksa Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Belite Bio Competitors Harmony Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FSDC) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FSDC Stock Free FSDC Stock Alerts